The duration of anticoagulation therapy varied widely in discordance with current guideline recommendations. Optimal duration of anticoagulation therapy should be defined according to the risk of recurrent VTE and bleeding as well as death.

incidence compared with patients without cancer. VTE is reported to be the second most frequent cause of death in patients with cancer undergoing chemotherapy. 4 Furthermore, VTE in patients with cancer could develop through not only hypercoagulability with cancer, but also treatmentrelated factors including new molecular target therapeutic agents, which have further increased the risk for development of VTE in the current era. 5 A recent study reported Cancer is a progressive disease with a high mortality rate despite intensive treatment, but many cancer patients are surviving longer because of progress in early diagnosis and treatment. 1,2 Thus, complications during the treatment course of cancer are becoming more clinically relevant. Cancer is a strong risk factor for the development of venous thromboembolism (VTE), and patients with cancer are reported to have a 7-fold higher

Late restenosis occurs after PCB angioplasty for DES-ISR lesions.

In patients with a sPESI score of 0, the 30-day mortality, recurrent venous thromboembolism and major bleeding rates were reasonably low. The sPESI score could be useful to identify candidates for early hospital discharge or home treatment.

No abstract